Table 3 Assignment of the first dose to subjects enrolled after the sentinel group.

From: Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

1st dose

Low dose (LD) (107.0 EID50%/dose)

Medium dose (MD) (107.5 EID 50%/dose)

High dose (HD) (108.0 EID 50%/dose)

IM

S19, S21, S23, S28, S30, S32, S37

S43, S45, S47, S52, S54, S56, S61

S67, S69, S71, S76, S78, S80, S85

IN

S20, S22, S24, S25, S26, S27, S29, S31, S33, S34, S35, S36, S38, S39, S40, S41, S42

S44, S46, S48, S49, S50, S51, S53, S55, S57, S58, S59, S60, S62, S63, S64, S65, S66

S68, S70, S72, S73, S74, S75, S77, S79, S81, S82, S83, S84, S86, S87, S88, S89, S90

  1. Evaluation by an Independent Safety Committee 7 days after the last HD vaccination.
  2. IM intramuscular, IN intranasal, S subject.
Back to article page